Home   About this service   Get the news  
+32 2 743 34 03

UCB [BE0003739530 / UCB]

UCB Media Room: Transparency notification UCB SA/NV


[07/04/2021 | 20:05]

** Transparency notification UCB SA/NV

=C2=B7 Notification referring to situation on 1 April 2021
=C2=B7 Threshold crossed: 3%
=C2=B7 Latest holding: 2.83%

Brussels (Belgium), 7 April 2021 =E2=80=93 20:00 (CEST) =E2=80=93 regulated=

1.=C2=A0=C2=A0Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large =
shareholdings, UCB SA/NV announces that it has filed a transparency notific=

The transparency notification dated 7 April 2021 has been submitted in acco=
rdance with Article 18 juncto Article 6 of the law of 2 May 2007 on the dis=
closure of large shareholdings, due to UCB covering its obligations towards=
employees in the framework of the Long Term Incentive plans of the UCB gro=
up. As a result thereof, voting rights relating to voting securities held b=
y UCB SA/NV crossed downwards the 3% threshold on 1 April 2021.=C2=A0

On 1 April 2021, UCB SA/NV owned 5 508 556 UCB shares with voting rights (v=
ersus 5 855 888 UCB shares in its previous notification dated 29 March 2021=
), representing 2.83% of the total number of shares issued by the company (=
194 505 658) (versus 3.01% in the notification dated 29 March 2020).=C2=A0

2.=C2=A0=C2=A0Content of the notification

=C2=B7 Reason for the notification: Acquisition or disposal of voting secur=
ities or voting rights
=C2=B7 Notification by: A person that notifies alone
=C2=B7 Person subject to the notification requirement:=C2=A0


=C2=B7 Date on which the threshold is crossed: 1 April 2021
=C2=B7 Threshold crossed (in %): 3%Denominator: 194 505 658
=C2=B7 Notified details:

=C2=B7 =C2=A0Additional information:=C2=A0

The disclosure obligation arose due to voting rights held by UCB SA crossin=
g downwards the 3% minimum threshold. The variation is due to UCB covering =
its obligations towards employees in the framework of the Long Term Incenti=
ve plans of the UCB group.=C2=A0

3.=C2=A0=C2=A0Further information

This press release and the detailed transparency notification are available=
on UCB SA/NV=E2=80=99s website via the following link (https://www.ucb.com=
/investors/UCB-shareholders) .

An updated overview of the UCB SA/NV large shareholdings will be available =
on UCB SA/NV=E2=80=99s website via the following link (https://www.ucb.com/=
investors/UCB-shareholders) .

Investor Relations
Antje Witte =C2=A0 =C2=A0 =C2=A0 =C2=A0 =C2=A0
Investor Relations, UCB
T +32.2.559.94.14 antje.witte@ucb.comIsabelle Ghellynck,
Investor Relations, UCB
T+32.2.559.9588, isabelle.ghellynck@ucb.com=C2=A0

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With approximately 8 400 peopl=
e in nearly 40 countries, the company generated revenue of =E2=82=AC 5.3 bi=
llion in 2020. UCB is listed on Euronext Brussels (symbol: UCB). Follow us =
on Twitter: @UCB_news

210407- Transparantieverklaring persbericht UCB (https://mb.cision.com/Publ=
ic/18595/3321279/a066539f3dfef890.pdf) GenericFile
210407 - Transparency notification UCB SA (https://mb.cision.com/Public/185=
95/3321279/bd5540ea22ccb50a.pdf) GenericFile
210407- Communication de presse UCB SA (https://mb.cision.com/Public/18595/=
3321279/86571c8a732803c6.pdf) Image
Chart 1 April 7 2021 (https://mb.cision.com/Public/18595/3321279/b8cb6c1e21=
f71479_org.png) Image
Chart 2 April 7 2021 (https://mb.cision.com/Public/18595/3321279/983ee51e1e=
If you would rather not receive future communications from UCB SA, please g=
o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x65905x1x6868579x24000=
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium=